Literature DB >> 7851008

The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

D Chargelegue1, C M Stanley, C M O'Toole, B T Colvin, M W Steward.   

Abstract

The affinity of anti-gag antibody was studied for up to 9 years (1984-1993) in sera from 15 HIV-1+ patients with haemophilia. On the basis of their 1993 clinical status patients were divided into two groups: (i) patients who remained asymptomatic (n = 9); and (ii) those who progressed to AIDS between late 1987 and 1993. The affinity constants of antibody for p24 and p17 were determined by a double isotope fluid-phase radioimmunoassay; and the relationships between antibody affinity and titre, patient clinical course, CD4 cell counts and p24 antigenaemia were analysed. The affinity of p24- and p17-specific antibody was up to 100 times greater in asymptomatic patients than in patients who progressed to AIDS. Patients who developed AIDS either lost or failed to develop high-affinity antibodies early in the infection. Asymptomatic patients maintained high-affinity antibodies for several years; however, in some of these patients the affinity of anti-p24 and p17 antibodies subsequently fell later in the study period. The presence of low-affinity antibody and progressive reduction in the titre of specific antibody were earlier predictors of disease onset than CD4 cell counts. The failure to either develop or maintain high affinity gag-specific antibody suggests an early impairment of T helper function in individuals who progressed to AIDS. The presence of antibody of high affinity could be essential in controlling virus replication and the onset of AIDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7851008      PMCID: PMC1534313          DOI: 10.1111/j.1365-2249.1995.tb05529.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides.

Authors:  C Partidos; C Stanley; M Steward
Journal:  Eur J Immunol       Date:  1992-10       Impact factor: 5.532

2.  Development of a sensitive ELISA for HIV-1 p24 antigen using a fluorogenic substrate for monitoring HIV-1 replication in vitro.

Authors:  D Chargelegue; C M O'Toole
Journal:  J Virol Methods       Date:  1992 Aug-Sep       Impact factor: 2.014

3.  Simple and efficient production of the core antigens of HIV-1, HIV-2 and simian immunodeficiency virus using pGEX expression vectors in Escherichia coli.

Authors:  H R Mills; N Berry; N R Burns; I M Jones
Journal:  AIDS       Date:  1992-04       Impact factor: 4.177

4.  Immunodiagnosis of feline immunodeficiency virus infection using recombinant viral p17 and p24.

Authors:  G Reid; M A Rigby; M McDonald; M J Hosie; J C Neil; O Jarrett
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

5.  Antibody affinity and valence in viral neutralization.

Authors:  S E Blank; G A Leslie; L W Clem
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

Review 6.  Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.

Authors:  T F Wolfs; P L Nara; J Goudsmit
Journal:  Chem Immunol       Date:  1993

7.  Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA.

Authors:  P A Underwood
Journal:  J Immunol Methods       Date:  1993-08-26       Impact factor: 2.303

8.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

9.  Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.

Authors:  R Cheingsong-Popov; C Panagiotidi; S Bowcock; A Aronstam; J Wadsworth; J Weber
Journal:  BMJ       Date:  1991-01-05

10.  A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.

Authors:  D Chargelegue; B T Colvin; C M O'Toole
Journal:  AIDS       Date:  1993-11       Impact factor: 4.177

View more
  13 in total

1.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

2.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection.

Authors:  Britta A Wood; Scott Carver; Ryan M Troyer; John H Elder; Sue VandeWoude
Journal:  J Immunol Methods       Date:  2013-08-14       Impact factor: 2.303

5.  Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Authors:  Derseree Archary; Rong Rong; Michelle L Gordon; Saikat Boliar; Maphuti Madiga; Elin S Gray; Anne-Sophie Dugast; Tandile Hermanus; Philip J R Goulder; Hoosen M Coovadia; Lise Werner; Lynn Morris; Galit Alter; Cynthia A Derdeyn; Thumbi Ndung'u
Journal:  Virology       Date:  2012-09-18       Impact factor: 3.616

6.  A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.

Authors:  Li Lu; Senthilkumar Palaniyandi; Rongyu Zeng; Yu Bai; Xindong Liu; Yunsheng Wang; C David Pauza; Derry C Roopenian; Xiaoping Zhu
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes.

Authors:  A Chawla; G Murphy; C Donnelly; C L Booth; M Johnson; J V Parry; A Phillips; A M Geretti
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

8.  Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.

Authors:  Carmem A de Freitas Oliveira; Mirthes Ueda; Rosemeire Yamashiro; Rosângela Rodrigues; Haynes W Sheppard; Luís Fernando de Macedo Brígido
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection.

Authors:  S Rusconi; A Riva; L Meroni; G Zehender; F Cocchi; L Scapellato; M Galli
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 10.  HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.